JP2016529218A5 - - Google Patents

Download PDF

Info

Publication number
JP2016529218A5
JP2016529218A5 JP2016522860A JP2016522860A JP2016529218A5 JP 2016529218 A5 JP2016529218 A5 JP 2016529218A5 JP 2016522860 A JP2016522860 A JP 2016522860A JP 2016522860 A JP2016522860 A JP 2016522860A JP 2016529218 A5 JP2016529218 A5 JP 2016529218A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
solvate
hydrate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016522860A
Other languages
English (en)
Japanese (ja)
Other versions
JP6360555B2 (ja
JP2016529218A (ja
Filing date
Publication date
Priority claimed from GBGB1311361.8A external-priority patent/GB201311361D0/en
Application filed filed Critical
Publication of JP2016529218A publication Critical patent/JP2016529218A/ja
Publication of JP2016529218A5 publication Critical patent/JP2016529218A5/ja
Application granted granted Critical
Publication of JP6360555B2 publication Critical patent/JP6360555B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016522860A 2013-06-26 2014-06-24 Ｎ−（４−ヒドロキシ−４−メチル−シクロヘキシル）−４−フェニル−ベンゼンスルホンアミド及びｎ−（４−ヒドロキシ−４−メチル−シクロヘキシル）−４−（２−ピリジル）ベンゼンスルホンアミド、並びにそれらの治療的使用 Active JP6360555B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1311361.8 2013-06-26
GBGB1311361.8A GB201311361D0 (en) 2013-06-26 2013-06-26 Compounds and their therapeutic use
PCT/GB2014/051921 WO2014207445A1 (en) 2013-06-26 2014-06-24 N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use

Publications (3)

Publication Number Publication Date
JP2016529218A JP2016529218A (ja) 2016-09-23
JP2016529218A5 true JP2016529218A5 (enExample) 2017-07-13
JP6360555B2 JP6360555B2 (ja) 2018-07-18

Family

ID=48998987

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016522860A Active JP6360555B2 (ja) 2013-06-26 2014-06-24 Ｎ−（４−ヒドロキシ−４−メチル−シクロヘキシル）−４−フェニル−ベンゼンスルホンアミド及びｎ−（４−ヒドロキシ−４−メチル−シクロヘキシル）−４−（２−ピリジル）ベンゼンスルホンアミド、並びにそれらの治療的使用

Country Status (28)

Country Link
US (4) US9624167B2 (enExample)
EP (1) EP3013799B1 (enExample)
JP (1) JP6360555B2 (enExample)
KR (1) KR102151299B1 (enExample)
CN (1) CN105492426B (enExample)
AU (1) AU2014300745B2 (enExample)
BR (1) BR112015031527B1 (enExample)
CA (1) CA2915075C (enExample)
CY (1) CY1119438T1 (enExample)
DK (1) DK3013799T3 (enExample)
EA (1) EA028077B1 (enExample)
ES (1) ES2641758T3 (enExample)
GB (1) GB201311361D0 (enExample)
HR (1) HRP20171611T1 (enExample)
HU (1) HUE034983T2 (enExample)
IL (1) IL243103B (enExample)
LT (1) LT3013799T (enExample)
ME (1) ME02834B (enExample)
MX (1) MX374328B (enExample)
NZ (1) NZ715192A (enExample)
PL (1) PL3013799T3 (enExample)
PT (1) PT3013799T (enExample)
RS (1) RS56256B1 (enExample)
SG (1) SG11201510646SA (enExample)
SI (1) SI3013799T1 (enExample)
SM (1) SMT201700503T1 (enExample)
WO (1) WO2014207445A1 (enExample)
ZA (1) ZA201600202B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
AU2015367528B2 (en) * 2014-12-17 2020-05-14 Pimco 2664 Limited N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use
GB201813312D0 (en) * 2018-08-15 2018-09-26 Modern Biosciences Ltd Compounds and their therapeutic use
GB201905520D0 (en) * 2019-04-18 2019-06-05 Modern Biosciences Ltd Compounds and their therapeutic use
EP4431090A1 (en) 2023-03-15 2024-09-18 Istesso 1 Limited Solfonamides acting as mitochondrial complex i modulator compounds
GB202308547D0 (en) 2023-06-08 2023-07-26 Istesso 2 Ltd Tnf inhibitor combination therapies
GB202309515D0 (en) 2023-06-23 2023-08-09 Istesso 2 Ltd JAK inhibitor and IL-6 inhibitor combination therapies
GB202315822D0 (en) 2023-10-16 2023-11-29 Istesso 3 Ltd Anti-fibrotic combination therapeutics
GB202317050D0 (en) 2023-11-07 2023-12-20 Istesso 2 Ltd Disease modifying anti-rheumatic drug combination therapies
EP4647071A1 (en) 2024-05-10 2025-11-12 Istesso Therapeutics Limited Mitochondrial complex i modulator for use in the treatment of arthritis

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB597810A (en) 1943-04-12 1948-02-04 Gen Printing Ink Corp Improvements in or relating to derivatives of diphenyl
DE1046220B (de) 1956-04-21 1958-12-11 Bayer Ag Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen
US4119784A (en) 1977-07-01 1978-10-10 American Cyanamid Company Anionic substituted sulfonamido biphenyls
DE3000519A1 (de) 1979-02-01 1980-08-14 Byk Gulden Lomberg Chem Fab Sulfonamido-alkansaeuren, ihre verwendung und herstellung sowie sie enthaltende arzneimittel
DE3535167A1 (de) 1985-10-02 1987-04-09 Boehringer Mannheim Gmbh Neue sulfonyl-phenyl(alkyl)amine, verfahren zu ihrer herstellung sowie arzneimittel
IL118325A0 (en) 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
AP9801222A0 (en) 1995-10-30 1998-06-30 Smithkline Beecham Corp Proatease inhibitors.
US5760028A (en) 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
WO1997033887A1 (en) 1996-03-15 1997-09-18 Du Pont Pharmaceuticals Company Spirocycle integrin inhibitors
PL331338A1 (en) 1996-07-22 1999-07-05 Monsanto Co Thiosulphonamidic metaloprotease inhibitors
PT938471E (pt) 1996-10-16 2002-05-31 American Cyanamid Co A preparacao e uso de acidos ortosulfonamidoarilhidroxamicos como inibidores de metaloproteinases de matriz e "tace"
DK0944619T3 (da) 1996-11-27 2007-02-05 Bristol Myers Squibb Pharma Co Hidtil ukendte integrinreceptorantagonister
AU6780398A (en) 1997-03-28 1998-10-22 Du Pont Merck Pharmaceutical Company, The Heterocyclic integrin inhibitor prodrugs
WO1998050342A1 (en) 1997-05-08 1998-11-12 Smithkline Beecham Corporation Protease inhibitors
DE19719621A1 (de) 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
PT877019E (pt) 1997-05-09 2002-05-31 Hoechst Ag Acidos diaminocarboxilicos substituidos
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
UA63990C2 (uk) 1998-01-23 2004-02-16 Авентіс Фарма Дойчланд Гмбх Сульфонамідні похідні, спосіб їх одержання та фармацевтична композиція на їх основі
EP1918278A1 (en) 1998-02-04 2008-05-07 Novartis AG Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
JPH11246527A (ja) 1998-03-02 1999-09-14 Shionogi & Co Ltd Ｍｍｐ−８阻害剤
DE19815547C1 (de) 1998-04-07 1999-12-02 Joachim Schmidt Haftmittel für Zahnprothesen
EP0960882A1 (en) 1998-05-19 1999-12-01 Hoechst Marion Roussel Deutschland GmbH Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
MXPA02009309A (es) 2000-03-21 2003-03-12 Procter & Gamble Inhibidores de las metaloproteasas n-sustituidas que contienen cadenas laterales carboxiclicas.
AU2001264595A1 (en) 2000-05-19 2001-12-03 Guilford Pharmaceuticals Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
AU2002228316A1 (en) 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Carbazole derivatives and their uses as heparanase inhibitors
US20050119305A1 (en) 2001-03-21 2005-06-02 Masao Naka Il-6 production inhibitors
JP2004535390A (ja) 2001-05-07 2004-11-25 スミスクライン・ビーチャム・コーポレイション スルホンアミド
PL368129A1 (en) 2001-08-09 2005-03-21 Ono Pharmaceutical Co, Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
GB0126157D0 (en) 2001-10-31 2002-01-02 Univ Aberdeen Therapeutic compounds
EP1491190A4 (en) 2002-03-27 2006-01-04 Shionogi & Co DECOMPOSITION INHIBITOR FOR CARTRIDGE EXTRACELLULAR MATRIX
JP4881558B2 (ja) 2002-09-04 2012-02-22 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
DE10251170A1 (de) 2002-10-31 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
WO2004073619A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
DK1638544T3 (da) 2003-05-07 2008-03-31 Univ Aberdeen Ketoner og reducerede ketoner som terapeutiske midler til behandling af knogletilstande
WO2004106290A1 (ja) 2003-05-14 2004-12-09 Kissei Pharmaceutical Co., Ltd. アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途
AR046330A1 (es) 2003-09-09 2005-12-07 Japan Tobacco Inc Inhibidor de dipeptidilpeptidasa iv
GB0324792D0 (en) 2003-10-23 2003-11-26 Sterix Ltd Compound
EP1696915A1 (en) 2003-12-19 2006-09-06 Pfizer, Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
EP1723132A1 (en) 2004-02-12 2006-11-22 Asterand Uk Limited Ep2 receptor agonists
GB0405193D0 (en) 2004-03-08 2004-04-21 Medical Res Council Compounds
US20080255240A1 (en) 2004-05-05 2008-10-16 Novo Nordisk A/S Sulfonamide Derivatives
GB0412553D0 (en) 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
US7470722B2 (en) 2004-06-10 2008-12-30 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
MX2007004862A (es) 2004-10-29 2007-05-09 Astrazeneca Ab Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias.
EP1659113A1 (en) 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
EA200702498A1 (ru) 2005-06-16 2008-06-30 Пфайзер Инк. N-(пиридин-2-ил)сульфонамидные производные
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
TW200720261A (en) 2005-08-31 2007-06-01 Sankyo Co Phenylene derivatives
DK2774925T3 (en) 2005-11-08 2017-02-27 Vertex Pharma Heterocyclic modulators of ATP binding cassette transporters
AU2006337137B2 (en) 2005-12-29 2012-06-14 Tersera Therapeutics Llc Multicyclic amino acid derivatives and methods of their use
US7560597B2 (en) 2007-03-08 2009-07-14 The University Court Of The University Of Aberdeen 2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds and their use as therapeutic agents
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
US8283368B2 (en) 2008-08-29 2012-10-09 The Regents Of The University Of Michigan Selective ligands for the dopamine 3 (D3) receptor and methods of using the same
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB0817207D0 (en) * 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
AU2015367528B2 (en) 2014-12-17 2020-05-14 Pimco 2664 Limited N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use

Similar Documents

Publication Publication Date Title
JP2016529218A5 (enExample)
JP2018509380A5 (enExample)
HRP20211877T1 (hr) Spojevi n-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamida i n-(4-hidroksi-4-metil-cikloheksil)-4- (2-piridil)-benzensulfonamida i njihova terapijska uporaba
HRP20171611T1 (hr) N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamidi i n-(4-hidroksi-4-metil-cikloheksil)-4-(2-piridil)-benzensulfonamidi i njihova terapeutska primjena
MX2021001583A (es) Formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ] fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboración y métodos de uso.
JP2019535720A5 (enExample)
Park et al. Olmutinib (BI 1482694; HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: efficacy and safety at the RP2D
JP2017530171A5 (enExample)
JP2018535967A5 (enExample)
JP2011529033A5 (enExample)
JP2017511311A5 (enExample)
JP2017525753A5 (enExample)
JP2016536286A5 (enExample)
ZA201607488B (en) Compounds for treating brain cancer
JP2015508103A5 (enExample)
JP2017520613A5 (enExample)
PH12019500965A1 (en) Crenolab for treating flt3 mutated proliferative disorders associated mutations
JP2016504325A5 (enExample)
EP3666273A3 (en) Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
JP2017507175A5 (enExample)
JP2020515582A5 (enExample)
IL275831A (en) Morphometric determination of gene type of cells using optical tomography to detect the mutational load of a tumor
JP2013544892A5 (enExample)
RU2011153613A (ru) Аминопиразол триазолотиадиазольные ингибиторы протеинкиназы с-мет
JP2020506884A5 (enExample)